Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05937672 · ClinicalTrials.gov registry record · Phase 3
Cold Atmospheric Plasma Device Extension Study
A Phase 3 study of Verruca Vulgaris and Molluscum Contagiosum, sponsored by Medical University of South Carolina.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT05937672: Recruiting Phase 3 study of Verruca Vulgaris and Molluscum Contagiosum, sponsored by Medical University of South Carolina.
NCT05937672 is a Phase 3 study of Verruca Vulgaris and Molluscum Contagiosum that is actively recruiting participants, run by Medical University of South Carolina. The registered enrollment target is 40 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05937672, a Phase 3 study of Verruca Vulgaris and Molluscum Contagiosum, is actively recruiting participants, sponsored by Medical University of South Carolina.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
Patients between 4-21 years of age with at least one wart or molluscum lesion are eligible to participate in this study. The duration of the study is a minimum of 4 weeks with the maximum duration of monthly treatments for one year, depending on lesion clearance. The number of lesions will be chosen by the dermatologist. Patients who opt to participate will receive non-thermal, or cold, atmospheric plasma to treat all lesions selected. Safety profile as well as changes in size, pain and appearance will be measured. Photographs and dermatologist impressions will be used to measure treatment response.
Primary Outcome
Absence of change in appearance of targeted lesion. Molluscum is defined as the visualization of a central umbilication with polylobular, white to yellow, amorphous structures. A peripheral crown of radiating or punctiform vessels may also be present. Warts are defined as grouped papillae, with dotted or loop vessels, and/or hemorrhagic points and lines often surrounded by a whitish halo.
Conditions Studied
Interventions
- DEVICE Floating electrode-dielectric barrier device (FE-DBD) cold atmospheric plasma (CAP)
Study Locations (1)
South Carolina
- Medical University of South Carolina - Charleston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2023-09-18 |
| Est. Completion | 2026-02-01 |
| Phase | Phase 3 |
What NCT05937672 shows while recruiting
NCT05937672 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (95% lower).
The record links to 2 conditions, with Verruca Vulgaris appearing as the primary indexed condition, and to 1 intervention - of which Floating electrode-dielectric barrier device (FE-DBD) cold atmospheric plasma (CAP) is the first listed.
NCT05937672 reports a single indexed study location in South Carolina.
Frequently Asked Questions
What is clinical trial NCT05937672 about?
NCT05937672 is a clinical study titled "Cold Atmospheric Plasma Device Extension Study". Patients between 4-21 years of age with at least one wart or molluscum lesion are eligible to participate in this study. The duration of the study is a minimum of 4 weeks with the maximum duration of monthly treatments for one year, depending on lesion clearance. The number of lesions will be chosen...
What is the current status of trial NCT05937672?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 40 participants. The study started on 2023-09-18. Estimated completion is 2026-02-01.
What conditions does trial NCT05937672 study?
This clinical trial studies the following conditions: Verruca Vulgaris, Molluscum Contagiosum.
What interventions are being tested in trial NCT05937672?
The interventions under investigation include: Floating electrode-dielectric barrier device (FE-DBD) cold atmospheric plasma (CAP) (DEVICE).
Who is sponsoring clinical trial NCT05937672?
This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05937672 being conducted?
This trial has 1 study location across South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Verruca Vulgaris
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05937672's enrollment target sits among peer trials
40 1879th of 2000 higher than 103 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI